You are viewing the site in preview mode
Skip to main content
|
Survival rates with a varied follow-up time
|
|
Author, year
|
Intervention group, HSCT+MSC
|
Control group, HSCT
|
P value
|
|
Follow-up, months
|
Survival
|
Follow-up, months
|
Survival
|
|
Ball, 2007 [16]
|
Range 3–28
|
OS 72%
|
Range 32–110
|
OS 63%
|
Not reported
|
|
RR 18%
|
RR 26%
|
Not reported
|
|
Daganzo, 2009 [30]
|
Median 7.4, range 1–22
|
OS 89%
|
Median 24, range 1–107
|
OS 53%
|
= 0.19
|
|
RR 11% at 22 months
|
RR 13% at 60 months
|
Not reported
|
|
DFS 71%
|
DFS 45%
|
Not reported
|
|
TRM 11% (95% CI 2–71)
|
TRM 37% (95% CI 25–54)
|
Not reported
|
|
Wu, 2013b [28]
|
Median 16.5, range 11–27
|
OS 75%
|
Median 18.5, range 12–31
|
OS 67%
|
> 0.05
|
|
RR 25%
|
RR 16.67%
|
Not reported
|
|
TRM 25%
|
TRM 33%
|
> 0.05
|
|
Wu, 2013a [34]
|
Median 27, range 24–31
|
OS 80%
|
Not reported
|
OS 56%
|
= 0.58
|
|
TRM 0%
|
TRM 22.2%
|
= 0.51
|
|
Survival measured at fixed measure points
|
|
Author, year
|
Intervention group, HSCT+MSCs
|
Control group, HSCT
|
P value
|
|
Measure time point, years
|
Survival
|
Measure time point, years
|
Survival
|
|
Baron, 2010 [32]
|
1
|
OS 60%
|
1
|
OS 38%
|
= 0.1
|
|
DFS 5%
|
DFS 0%
|
> 0.05
|
|
TRM 10%
|
TRM 37%
|
= 0.02*
|
|
RR 30%
|
RR 25%
|
= 0.9
|
|
Zhang, 2015 [37]
|
1
|
OS 72.7%
|
1
|
OS 85.2%
|
= 0.472
|
|
RR 9.1%
|
RR 22.2%
|
= 0.396
|
|
CRR 9.1%
|
CRR 33.3%
|
= 0.093*
|
|
Xiang, 2017 [13]
|
1
|
OS 87%
|
1
|
OS 75%
|
= 0.202
|
|
CRR 16%
|
CRR 25%
|
= 0.351
|
|
Lee, 2013 [14]
|
2
|
OS 85.7%
|
2
|
OS 55.6%
|
= 0.15
|
|
Liu, 2011 [22]
|
2
|
OS 69.7%
|
2
|
OS 64.3%
|
= 0.737
|
|
RR 12.8%
|
RR 9.3%
|
= 0.721
|
|
MacMillan, 2009 [31]
|
3
|
OS 75% (95% CI 45–100)
|
3
|
OS 46% (95% CI 26–66)
|
= 0.38
|
|
Ning, 2008 [24]
|
3
|
OS 40%
|
3
|
OS 66.7%
|
Not reported
|
|
DFS 30%
|
DFS 66.7%
|
= 0.035*
|
|
RR 60.0%
|
RR 20%
|
= 0.020*
|
|
Bernardo, 2011 [15]
|
3
|
OS 63% (95% CI 43–97)
|
3
|
OS 64% (95% CI 48–79)
|
NS
|
|
DFS 67% (95% CI 41–94)
|
DFS 56% (95% CI 40–72)
|
NS
|
|
TRM 8% (95% CI 1–51)
|
TRM 21% (95% CI 11–38)
|
NS
|
|
RR 25% (95% CI 9–67)
|
RR 23% (95% CI 13–42)
|
NS
|
|
Kang, 2017 [38]
|
3
|
OS 70.6%
|
3
|
OS 23.1
|
= 0.004*
|
|
DFS 52.9%
|
DFS 0%
|
= 0*
|
|
TRM 11.8%
|
TRM 46.2%
|
= 0.017*
|
|
RR 32.4%
|
RR 53.8%
|
= 0.199
|
|
Ghavamzadeh, 2017 [39]
|
3
|
OS 70%
|
3
|
OS 61%
|
= 0.78
|
|
DFS 54%
|
DFS 61%
|
= 0.35
|
|
Mareika, 2016 [29]
|
> 3
|
OS (90 ± 9.5)%
|
> 3
|
OS (83 ± 10.7)%
|
Not reported
|
|
RR 10%
|
RR 0%
|
Not reported
|
- OS overall survival, TRM/NRM treatment-related mortality/non-relapse mortality, RR relapse rate, DFS disease free survival, CRR cumulative relapse rate, NS not significant
- *Statistically significant
